Ratios Reveal: Breaking Down BioNTech SE ADR (BNTX)’s Financial Health

For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

BioNTech SE ADR (NASDAQ: BNTX) closed the day trading at $80.68 down -6.40% from the previous closing price of $86.20. In other words, the price has decreased by -$6.40 from its previous closing price. On the day, 1.11 million shares were traded. BNTX stock price reached its highest trading level at $82.74 during the session, while it also had its lowest trading level at $80.23.

Ratios:

For a better understanding of BNTX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.98 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.32. For the most recent quarter (mrq), Quick Ratio is recorded 11.16 and its Current Ratio is at 11.38. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Evercore ISI on May 14, 2024, initiated with a In-line rating and assigned the stock a target price of $100.

On February 23, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $127.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNTX now has a Market Capitalization of 19443073024 and an Enterprise Value of 3749512192. As of this moment, BioNTech’s Price-to-Earnings (P/E) ratio for their current fiscal year is 168.54. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.50 while its Price-to-Book (P/B) ratio in mrq is 0.89. Its current Enterprise Value per Revenue stands at 1.374 whereas that against EBITDA is -22.466.

Stock Price History:

Over the past 52 weeks, BNTX has reached a high of $125.83, while it has fallen to a 52-week low of $78.02. The 50-Day Moving Average of the stock is -9.60%, while the 200-Day Moving Average is calculated to be -14.20%.

Shares Statistics:

Over the past 3-months, BNTX traded about 726.47K shares per day on average, while over the past 10 days, BNTX traded about 494050 shares per day. A total of 237.73M shares are outstanding, with a floating share count of 237.14M. Insiders hold about 0.25% of the company’s shares, while institutions hold 17.80% stake in the company. Shares short for BNTX as of 1721001600 were 3368893 with a Short Ratio of 4.64, compared to 1718323200 on 2743478. Therefore, it implies a Short% of Shares Outstanding of 3368893 and a Short% of Float of 6.5799996.

Most Popular